References:
  1. Urano M, Abe M, Horibe Y, Kuroda M, Mizoguchi Y, Sakurai K, Naito K. Sclerosing mucoepidermoid carcinoma with eosinophilia of the salivary glands. Pathol Res Pract. 2002;198(4):305-10.
  2. Tasaki T, Matsuyama A, Tabata T, Suzuki H, Yamada S, Sasaguri Y, Hisaoka M. Sclerosing mucoepidermoid carcinoma with eosinophilia of the salivary gland: case report and review of the literature. Pathol Int. 2013 Feb;63(2):125-31.
  3. Kobayashi Y, Satoh K, Aizawa T, Urano M, Kuroda M, Mizutani H. Local recurrence of sclerosing mucoepidermoid carcinoma with eosinophilia in the upper lip: a case report. J Med Case Rep. 2015 Feb 24;9:41. doi: 10.1186/s13256-015-0525-8. PMID: 25888867; PMCID: PMC4344751.
  4. Harada H, Toyozumi Y, Sasaguri T, Kuyama K, Nakatsuka SI, Kurose A. Sclerosing mucoepidermoid carcinoma of the salivary glands: report of three cases with special concern to the counterpart accompanied by eosinophilia. Med Mol Morphol. 2021 Sep;54(3):265-274.
  5. Alena Skalova et al., editors. Chapter 5. Salivary gland tumours in: WHO Classification of Tumours Editorial Board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer; forthcoming. (WHO classification of tumours series, 5th ed.; vol. 9).
  6. Chan JK, Albores-Saavedra J, Battifora H, Carcangiu ML, Rosai J. Sclerosing mucoepidermoid thyroid carcinoma with eosinophilia: a distinctive low-grade malignancy arising from the metaplastic follicles of Hashimoto’s thyroiditis. Am J Surg Pathol. 1991;15:438–48.
  7. Shah AA, La Fortune K, Miller C, Mills SE, Baloch Z, LiVolsi V, Dacic S, Mahaffey AL, Nikiforova M, Nikiforov YE, Seethala RR. Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia: a clinicopathologic and molecular analysis of a distinct entity. Mod Pathol. 2017 Mar;30(3):329-339.
  8. Heptinstall L, Carroll C, Siddiqi J, Kamel D, Petkar M. Sclerosing Mucoepidermoid Carcinoma of the Submandibular Gland Presenting as Chronic Sialadenitis: A Case Report and Review of Literature. Head Neck Pathol. 2017 Dec;11(4):506-512.
  9. Jee KJ, Persson M, Heikinheimo K, Passador-Santos F, Aro K, Knuutila S, Odell EW, Mäkitie A, Sundelin K, Stenman G, Leivo I. Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma. Mod Pathol. 2013 Feb;26(2):213-22.
  10. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, van de Rijn M. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):690-5.
  11. Cheung FMF, So TYC, Sung THT, Lam YL. Diffuse-Type Tenosynovial Giant Cell Tumour Involving Bone Masquerading as Langerhans Cell Histiocytosis. Case Rep Med. 2022 Sep 15; 2022:1992541.
  12. Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O’Connell JX, Huntsman D, van de Rijn M, Gilks CB, West RB. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007 Jun;31(6):970-6.
Acknowledgement: All authors have no conflicts of interest in this publication. We would like to thank the patient concerned for signing the informed consent for publication of clinical data and figures. We would like to thank Department of Pathology, Queen Mary Hospital, for the slide review.